Medexus Pharmaceuticals Inc.
MDP.TO
TSX
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -3,443.75% | 125.40% | -161.05% | 193.31% | -175.44% |
| Total Depreciation and Amortization | 1.32% | -0.16% | 0.08% | -0.41% | 38.72% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 116.35% | -2.25% | 281.36% | 275.66% | -107.72% |
| Change in Net Operating Assets | -79.10% | 1,426.55% | -150.00% | -6.30% | -52.16% |
| Cash from Operations | -51.64% | 134.67% | -14.85% | 72.19% | -66.08% |
| Capital Expenditure | 84.21% | -171.43% | 94.40% | -135.85% | 13.11% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -17.44% | 75.30% | -346.61% | 81.64% | -436.00% |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -50.00% | -- | -- | -- | 100.00% |
| Cash from Investing | -47.09% | -227.85% | 29.30% | -13.48% | -330.69% |
| Total Debt Issued | -100.01% | -- | -- | -- | -- |
| Total Debt Repaid | 85.47% | -1,761.97% | 92.56% | -363.27% | 0.06% |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -208.27% | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 26.36% | -16.74% | 40.19% | 5.13% | 29.31% |
| Cash from Financing | -232.81% | 296.50% | 90.18% | -207.42% | 439.97% |
| Foreign Exchange rate Adjustments | -280.85% | 238.24% | -147.22% | -52.94% | 150.66% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -251.09% | 11,316.33% | 100.33% | -194.26% | 958.04% |